Eagle’s Eye View: Clopidogrel vs. Aspirin Following PCI
In this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel may offer a long-term edge over aspirin after percutaneous coronary intervention (PCI). Finally, Dr. Eagle summarizes HELIUS cohort findings demonstrating that LDL-C, Lp(a), and hsCRP provide complementary, independent insights for identifying long-term atherosclerotic cardiovascular disease (ASCVD) risk across diverse ethnic populations.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiac Surgery, Cardiovascular Care Team, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Advanced Lipid Testing, Lipid Metabolism, Nonstatins, Acute Heart Failure, Heart Failure and Cardiac Biomarkers, Heart Transplant, Interventions and Structural Heart Disease
Keywords: EaglesEyeView, Heart Transplantation, Cardiomyopathy, Hypertrophic, Heart Failure, Risk Assessment, Genotype, Hemodynamics, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Aortic Valve, Heart Valve Prosthesis, Prostheses and Implants, Heart Valve Diseases, Percutaneous Coronary Intervention, Dual Anti-Platelet Therapy, Clopidogrel, Aspirin, Lipoprotein(a), Cholesterol, LDL, C-Reactive Protein, Cardiovascular Diseases, Risk Factors, Biomarkers
